A clinical trial with long-term follow-up found that administering BCG vaccine during the active phase of COVID-19 appeared ...

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of ...

Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance of Th1/Th17–Th2–regulatory T-cell axis. It is important to determine the expression and potential role of ...

BCG immunotherapy showed a significant advantage over mitomycin C with regard to recurrence (hazard ratio 2.0). The results are impressive, even with such a long follow-up period and as few as 45 ...

Bladder cancer ranks as the 10th most commonly diagnosed cancer globally, affecting both men and women. Approximately 75% of patients are initially diagnosed with non-muscle invasive bladder cancer ...

Bacillus Calmette-Guérin (BCG). The novel treatment, cretostimogene grenadenorepvec, is an oncolytic immunotherapy, meaning it is a virus designed to selectively replicate in and break down ...